Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Accumulated Expenses (2016 - 2025)

Ptc Therapeutics has reported Other Accumulated Expenses over the past 14 years, most recently at $16.5 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $16.5 million for Q4 2025, down 20.03% from a year ago — trailing twelve months through Dec 2025 was $16.5 million (down 20.03% YoY), and the annual figure for FY2025 was $16.5 million, down 20.03%.
  • Other Accumulated Expenses for Q4 2025 was $16.5 million at Ptc Therapeutics, down from $17.4 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for PTCT hit a ceiling of $28.3 million in Q2 2025 and a floor of $1.2 million in Q1 2021.
  • Median Other Accumulated Expenses over the past 5 years was $11.3 million (2023), compared with a mean of $12.4 million.
  • Peak annual rise in Other Accumulated Expenses hit 911.12% in 2021, while the deepest fall reached 65.7% in 2021.
  • Ptc Therapeutics' Other Accumulated Expenses stood at $12.6 million in 2021, then decreased by 4.63% to $12.1 million in 2022, then decreased by 11.45% to $10.7 million in 2023, then skyrocketed by 92.97% to $20.6 million in 2024, then dropped by 20.03% to $16.5 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $16.5 million (Q4 2025), $17.4 million (Q3 2025), and $28.3 million (Q2 2025) per Business Quant data.